Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2024 | $101.00 | Buy → Hold | Deutsche Bank |
| 7/1/2024 | Outperform → Mkt Perform | William Blair | |
| 6/7/2023 | $97.00 | Buy → Hold | Truist |
| 4/21/2023 | $87.00 | Neutral | Cantor Fitzgerald |
| 3/13/2023 | $93.00 | Equal Weight | Barclays |
| 10/27/2022 | Outperform → Mkt Perform | Raymond James | |
| 8/2/2022 | $145.00 → $95.00 | Neutral → Sell | UBS |
| 6/29/2022 | $128.00 | Hold | Stifel |
Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.
Amedisys (NASDAQ:AMED) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.18 by 11.86 percent. This is a 3.65 percent decrease over earnings of $1.37 per share from the same period last year. The company reported quarterly sales of $591.19 million which beat the analyst consensus estimate of $578.82 million by 2.14 percent. This is a 6.91 percent increase over sales of $552.97 million the same period last year.
William Blair analyst Matt Larew downgrades Amedisys (NASDAQ:AMED) from Outperform to Market Perform.
BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million
All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo
BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th
10-Q - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
3 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
Deutsche Bank downgraded Amedisys from Buy to Hold and set a new price target of $101.00
William Blair downgraded Amedisys from Outperform to Mkt Perform
Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00
BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa
BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o
BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is inclusive of $11.5 million in costs associated with with our merger transactions, compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted s
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month Periods Ended September 30, 2024 and 2023 Net service revenue increased $31.5 million to $587.7 million compared to $556.2 million in 2023.Net income attributable to Amedisys, Inc. of $16.9 million, which is inclusive of merger-related expenses totaling $16.7 million ($16.7 million, net of tax) compared to net income attributable to Amedisys, Inc. of $26.0 million, which is inclusive of merger-related expenses totaling $5.0 million ($4.7 million, net of tax) in 2023.Net income attribut
BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by Strategic Healthcare Programs (SHP) for achieving the highest overall HHCAHPS patient satisfaction or CAHPS Hospice caregiver satisfaction scores of all eligible SHP clients in 2023. This includes 14 care centers awarded Premier Performer, ranking in the top 5%, and 78 care centers awarded Superior Performer, ranking in the top 20%. Thirteen care centers achieved an award in each of the last 5 years of the SHPBest program. "Nothing we do is possible without our incredible ca
NASHVILLE, Tenn., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today, Contessa Health, a subsidiary of Amedisys Inc. (NASDAQ:AMED), announced they have been selected by the Centers for Medicare & Medicaid Services (CMS) to participate in a new Medicare alternative payment model designed to support people living with dementia and their caregivers. Under CMS' Guiding an Improved Dementia Experience (GUIDE) Model, Contessa will be one of almost 400 participants building Dementia Care Programs (DCPs) across the country, working to increase care coordination and improve access to services and supports, including respite care, for people living with dementia and their caregivers. "CMS is excited to
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)